• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through September 2025 

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through September 2025 

by Truveta Research | Oct 24, 2025 | Research, Research Insights

Respiratory virus–associated hospitalizations declined overall in September 2025 (–27.1%). COVID-associated hospitalizations declined substantially (-45.1%) but still account for the most virus-associated hospitalizations in those aged 65 and older (1.1%). Rhinovirus...
Exploring anemia burden and treatment patterns in patients with chronic kidney disease and diabetes

Exploring anemia burden and treatment patterns in patients with chronic kidney disease and diabetes

by Truveta Research | Oct 21, 2025 | Featured research, Research, Research Insights

In patients with CKD and diabetes, anemia prevalence and severity increased from stage 1 to stage 5, with overall anemia rising from 46.4% to 85.0% and severe anemia from 2.5% to 11.8% Erythropoiesis-stimulating agents (ESAs) and IV iron use rose as hemoglobin levels...
GLP-1 RA prescription trends: January 2018 – September 2025

GLP-1 RA prescription trends: January 2018 – September 2025

by Truveta Research | Oct 20, 2025 | Featured research, Research, Research Insights

Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in September 2025 remained stable relative to June 2025 (+4.6%). As of September 2025, GLP-1 prescriptions account for 6.5 out of every 100 prescriptions in the US. Tirzepatide continues...
Associations of nutrition counseling, insulin, and metformin therapy with post-GTT weight gain in a large pregnancy cohort

Associations of nutrition counseling, insulin, and metformin therapy with post-GTT weight gain in a large pregnancy cohort

by Truveta Research | Oct 17, 2025 | Research, Research Insights

Nearly half of patients with gestational diabetes mellitus (GDM) received nutrition counseling within 45 days of diagnosis, while smaller proportions initiated insulin (15%) or metformin (10%). Despite being the first-line intervention, about half of patients with GDM...
Real-world patterns of glucose tolerance testing and gestational diabetes in pregnancy

Real-world patterns of glucose tolerance testing and gestational diabetes in pregnancy

by Truveta Research | Oct 17, 2025 | Research, Research Insights

Nearly one-quarter of patients exceeded the 140 mg/dL threshold on the 1-hour glucose tolerance test. However, about 1 in 10 patients with elevated values did not receive recommended follow-up testing or a GDM diagnosis, highlighting gaps in adherence to clinical...
Exploring gestational weight gain and newborn birth weight

Exploring gestational weight gain and newborn birth weight

by Truveta Research | Oct 2, 2025 | Research, Research Insights

Mothers who gained more weight during pregnancy had heavier infants and mothers who lost weight during pregnancy had lighter infants. Mothers who gained less weight (particularly <15 pounds) and who lost weight during their pregnancy had increased risk of a...
Exploring gestational weight gain and loss

Exploring gestational weight gain and loss

by Truveta Research | Oct 2, 2025 | Research, Research Insights

Across their pregnancies, mothers had an average of 12 weight measurements, allowing us to construct a longitudinal ‘journey’ of their weight change. Mothers gained an average of 31 pounds across their pregnancies and 45% of mothers had evidence of some weight loss....
Impact of the CVS GLP-1 formulary change: Trends in switching

Impact of the CVS GLP-1 formulary change: Trends in switching

by Truveta Research | Sep 5, 2025 | Research, Research Insights

In July 2025, following the CVS formulary change, 9.6% of patients on AOM tirzepatide switched to a different drug. This was more than a 16-fold increase compared with the average earlier in the year. Among AOM tirzepatide users who switched to a different GLP-1...
Impact of the CVS GLP-1 formulary change: Trends in prescribing

Impact of the CVS GLP-1 formulary change: Trends in prescribing

by Truveta Research | Sep 5, 2025 | Research, Research Insights

AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025 after the CVS GLP-1 formulary change. In contrast, AOM semaglutide increased by +0.1 points...
ISPE 2025: Real-world data survival patterns in glioblastoma patients

ISPE 2025: Real-world data survival patterns in glioblastoma patients

by Truveta Research | Aug 22, 2025 | Research, Research Insights

Authors: Mantas Dmukauskas, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah Blach, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Amy Wu ⊕Truveta, Inc, Bellevue, WA The survival rate for patients with glioblastoma (GBM) differs significantly by...
ISPE 2025: Active surveillance of mosquito-borne diseases in the United States

ISPE 2025: Active surveillance of mosquito-borne diseases in the United States

by Truveta Research | Aug 22, 2025 | Research, Research Insights

Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA Truveta Data is well-suited to...
ISPE 2025: Active surveillance of foodborne diseases in the United States

ISPE 2025: Active surveillance of foodborne diseases in the United States

by Truveta Research | Aug 22, 2025 | Research, Research Insights

Authors: Katie Kendrick, MPH ⊕Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Sunny Guin, PhD ⊕Truveta, Inc, Bellevue, WA, Agnes Pastwa ⊕Truveta, Inc, Bellevue, WA, Sarah Platt, MS ⊕Truveta, Inc, Bellevue, WA Truveta Data is well-suited to...
« Older Entries

Share this


Recent posts

  • Real-time monitoring of respiratory virus-associated hospitalizations: Trends through September 2025 
  • Exploring anemia burden and treatment patterns in patients with chronic kidney disease and diabetes
  • GLP-1 RA prescription trends: January 2018 – September 2025

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.